Review of Infliximab Therapy in Chronic Inflammatory Diseases: Mechanisms and Clinical Outcomes
Received Date: Apr 01, 2024 / Published Date: Apr 30, 2024
Abstract
Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), has revolutionized the treatment landscape of chronic inflammatory diseases. This review comprehensively explores the mechanisms of action, therapeutic indications, and clinical outcomes associated with Infliximab therapy across various conditions.
Citation: Khanduja D (2024) Review of Infliximab Therapy in Chronic InflammatoryDiseases: Mechanisms and Clinical Outcomes. J Pulm Res Dis 8: 194.
Copyright: © 2024 Khanduja D. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 129
- [From(publication date): 0-2024 - Dec 22, 2024]
- Breakdown by view type
- HTML page views: 98
- PDF downloads: 31
